AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: 0.5g qid
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: 0.5g qid
Study NCT05010941 — intervention group
Intervention type: DEVICE
Intervention: Hypotension Prediction Index
Description: Hypotension Prediction Index monitored via radial arterial line
Study NCT04699292 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery
Study NCT04699292 — intervention group
Intervention type: RADIATION
Intervention: Preoperative RT 36Gy
Description: Preoperative radiotherapy to 36Gy (equivalent)
Study NCT04699292 — intervention group
Intervention type: RADIATION
Intervention: Preoperative RT 50Gy
Description: Preoperative radiotherapy to 50Gy (equivalent)
Study NCT04699292 — intervention group
Intervention type: RADIATION
Intervention: Postoperative RT 50-66Gy
Description: Postoperative radiotherapy to 50-66Gy (equivalent)
Study NCT04699292 — intervention group
Intervention type: RADIATION
Intervention: RT 36Gy
Description: Definitive radiotherapy to 36Gy (equivalent)
Study NCT06276218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clavicular brace
Description: Clavicular brace for conservative treatment of closed midshaft clavicular fractures
Study NCT06276218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clavicular brace
Description: Clavicular brace for conservative treatment of closed midshaft clavicular fractures
Study NCT04691622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus -specific T-cell (NST) therapy
Description: Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.
Study NCT05110794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered Orally.
Study NCT04718285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Oral Tablet
Description: 3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
Study NCT04718285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast plus Favicovir (Favipiravir)
Description: 200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
Study NCT04718285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favicovir (Standard Treatment)
Description: 200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
Study NCT06459167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The position adopted when patients undergoing procedure or surgery
Description: For patients requiring sedation for procedures or surgery, they are randomly assigned either to supine position or lateral position before they are sedated, and kept during procedure or surgery.
Study NCT05950607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAIN AD 2.0
Description: The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. .
Study NCT05950607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRAIN AD 2.0
Description: The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. .
Study NCT05709197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Braun anastomosis
Description: Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.
Study NCT05709197 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Child reconstruction
Description: Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
Study NCT05410587 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fracture Monitor (implantable device class III)
Description: Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
Study NCT04969965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aumolertinib
Description: EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
Study NCT05904522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy for histopathological examination
Study NCT05815004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene therapy
Description: AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
Study NCT05815004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gene therapy
Description: AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
Study NCT05815004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme Replacement Agent
Description: A hydrolytic lysosomal glucocerebrosidase-specific enzyme
Study NCT05308589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPPF
Description: Continuous Postoperative Pericardial Flush
Study NCT04899752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
Study NCT06699966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
Study NCT06699966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
Study NCT06208410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS105
Description: JS105 is administered once daily, orally
Study NCT06208410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
Study NCT06208410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib Isetionate Tablets
Description: Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
Study NCT06208410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
Study NCT06208410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection (Albumin Bound)
Description: Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
Study NCT06208410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib Capsules
Description: Fluzoparib Capsules is administered once daily, orally
Study NCT06208410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate Tablets
Description: Pyrotinib Maleate Tablets is administered once daily, orally
Study NCT06208410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Tablets
Description: Capecitabine Tablets is administered once daily, orally
Study NCT05620160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216
Description: RAY1216（tablet）
Study NCT05620160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo （tablet）
Study NCT05454956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm
Study NCT05454956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03 Vehicle
Description: Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
Study NCT04789161 — intervention group
Intervention type: PROCEDURE
Intervention: double kissing crush stenting
Description: Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
Study NCT04789161 — intervention group
Intervention type: PROCEDURE
Intervention: double kissing culotte stenting
Description: Patients with true bifurcation lesion treating with double kissing culotte stenting technique
Study NCT05244577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Tablets
Description: Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant
Study NCT05244577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo,Ondansetron,Dexamethasone,Fosaprepitant
Study NCT05396729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
Study NCT05461794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: administered orally
Study NCT05461794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously
Study NCT05461794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: administered intravenously
Study NCT05461794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: administered intravenously
Study NCT05168267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
Study NCT05765149 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, no intervention will be implemented.
Study NCT04815122 — intervention group
Intervention type: RADIATION
Intervention: SPECT TRODAT-1
Description: The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
Study NCT06607081 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention
Description: The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.
Study NCT05118984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin capsule (Zithromax, Pfizer) (250 mg)
Description: Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
Study NCT05118984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A treatment that has no active properties
Study NCT06276582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Screening for neonatal jaundice with a mobile health device
Description: Picterus Jaundice Pro will be used to screen for neonatal jaundice by taking 6 photos of the newborns skin, where the Picterus calibration card is place.
Study NCT05700760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)
Description: Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
Study NCT05700760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care as Usual (CAU)
Description: Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
Study NCT05173610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: Stereotactic body radiotherapy (SBRT)
Description: Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma.~1. Target delineation The GTV is set using diagnostic CT, MRI, PET-CT, etc. CTV is delineated including the microscopic range in GTV and internal margin using 4D-CT. The PTV is expanded by considering the uncertainty of the daily patient posture setting and placement.~2. Radiotherapy All patients are treated using 3D-CRT, IMRT, or VMAT. Total dose and fractionations will be determined depending on the location and character of the metastasized tumor. Detailed radiation prescriptions is summarized in the following paragraph.~   i. Liver: 48-60 Gy in 4 fractions ii. Lung: 45-60 Gy in 3-4 fractions iii. Brain: 27-30 Gy in 3-5 fractions iv. bone: 24-40 Gy in 3-5 fractions v. adrenal gland: 30-60 Gy in 3-8 fractions vi. other organ: depending on the clinicians' decision
Study NCT04994873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP
Description: Behavioral intervention to increase positive affect
Study NCT04994873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced TAU
Description: Standard care plus a phone app with a personalized safety plan
Study NCT03276052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide 400 μg
Description: Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
Study NCT05489653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mixed music
Description: Learn about the effects of listening to music and doing activities with it on sleep.
Study NCT05489653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mixed music
Description: Learn about the effects of listening to music and doing activities with it on sleep.
Study NCT03402789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
Study NCT03402789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet daily plus 2 hours of eye patching daily
Study NCT06059521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software refraction with Eye Test Technology in a mobilerone
Description: Refraction is done by software App by a mobilerone software installed.
Study NCT06059521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retinoscopy
Description: Retinoscopy is an objective refraction method with retinoscope.
Study NCT05462977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group exercise program
Description: Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
Study NCT06284993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture(more frequent)
Description: With the patient in a prone position, the local skin will be routinely sterilized, Ashi points will be perpendicularly inserted into the plantar fascia layer with a depth of approximately 15-20 mm depending on the location. BL57, KI3, and BL60 will be punched perpendicularly 10-15 mm deep into the skin. All needles except the Ashi points will be manually stimulated with small, equal manipulations of lifting, thrusting, twirling, and rotating to achieve De qi (a sensation including soreness, numbness, distention, and heaviness), and the practitioner has a feeling of needle sinking and tightness. The electroacupuncture instrument is connected to the needle handle of BL57 and BL60 respectively. During the needle retention period, except for BL57 and BL60, which are connected to the electroacupuncture instrument, Ashi points and KI3 perform a small and uniform twisting technique three times every 10 min, and a total of 3 times within 30min.
Study NCT06284993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture(less frequent)
Description: The intervention is the same as Group M except that the frequency of acupuncture will be once per week acupuncture. During the treatment period, in addition to acupuncture, patients will be visited twice a week for a total of 8 visits by telephone or in person. If the content of the visit aligns with the established efficacy evaluation visit in the program, it will be carried out as planned. If not, the patient will be inquired about the progress of their condition since the previous treatment, any rescue medication taken, and other relevant information. Visits that do not involve improvement in relevant indicators of study concern do not need to be recorded.~The electroacupuncture will last for 30 min and will be performed three sessions per week or one session per week for a total of 12 or 4 sessions in four consecutive weeks. Participants in both groups will be treated and (or) evaluated separately.